Medical Marijuana, Inc.’s HempMeds Educates A4M Doctors on Anti-Aging Cannabis Products

Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMeds(TM) — a corporate portfolio company of Medical Marijuana, Inc. — is dramatically expanding its brand presence though natural hemp cannabidiol (CBD) education at the American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas, Dec. 11-13. The A4M global conference on anti-aging, regenerative and aesthetic medicine markets to more than 26,000 physicians and scientists from 120 countries.

At the A4M Las Vegas conference, Dr. James J. Bradstreet MD, MD(H), FAAFP, known for his collaboration on cannabinoid research, is conducting the CME lecture on Thursday, Dec. 11: Understanding the Pivotal Role of the Endocannabinoid System and Cannabinoid Ligands in Aging, Obesity, Heart Disease, Neurodegeneration and Pain. The A4M is also releasing a scholarly article on cannabinoids by Dr. Bradstreet at their 2014 Las Vegas World Congress.

Dr. “Doc Rob” Streisfeld, NDM, a natural products and cannabis industry consultant, is leading a group panel discussion on cannabis in the natural products industry during a sponsored evening networking reception. Streisfeld states: “Cannabis in natural products is one of the industry’s fastest-growing segments. In the cannabis spectrum, hemp has surpassed coconut oil-based products in retail popularity. Consumers are demanding retail-ready cannabis products and we are looking forward to discussion from the A4M medical community on the future of cannabis in natural anti-aging products.”

The A4M conference identifies the following nutraceutical and anti-aging market opportunities:

  • The anti-aging market is estimated to be worth $292 billion globally by 2015
  • 10% of the world’s population is aged 60+ and is expected to represent 22% by 2050
  • The global nutraceutical market is projected to exceed $243 billion by 2015
    The current US nutraceutical market is valued at $17.1 billion
  • Sixty percent (60%) of Americans age 65+ are pursuing anti-aging interventions, including hormone replacement therapies and dietary supplementation
  • Dietary supplement sales were $25 billion in 2010
    Thirty-three percent (33%) of adults take supplements on the specific advice of their doctor

Those planning to attend these conferences should visit the A4M conference website for admission requirement details.

“We are very excited to continue educating the doctors and professionals gathered at A4M on the emerging world of natural CBD hemp oil and the exciting new developments at HempMeds,” states Andrew Hard, a spokesperson for HempMeds. “As we head into 2015, the news and updates for this emerging industry are going to shock the world, and we’re very eager to spread the good news.”

For more information on HempMeds(TM) and their all-natural CBD hemp oil products, visit: The Company invites the public to get involved in the conversation on the expanding cannabis industry with HempMeds(TM) through the Company’s social media websites on Facebook and Twitter.

About HempMeds

HempMeds(TM) offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds(TM) is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds(TM) is the communication hub for the Medical Marijuana Inc. portfolio of companies.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at:


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.


For further information, please contact:
Investor Relations contact:
Perry Coleman
Medical Marijuana, Inc.
P. 443-453-5088
Public Relations contact:
Andrew Hard
P. 858-380-5478
Corporate contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report